Table 1.

Baseline characteristics of 172 patients with nontuberculous mycobacteria enrolled in follow-up study

	Met Case Criteria (n = 102)	Did Not Meet Case Criteria (n = 70)
Female sex	70 (68.6)	36 (51.4)
Age at isolation, yr, median (range)	67 (12–92)	67 (26–93)
Species
Mycobacterium avium complex	91 (89.2)	52 (74.3)
Mycobacterium abscessus/chelonae complex	6 (5.9)	2 (2.9)
Mycobacterium fortuitum complex	0 (0)	4 (5.7)
Other (includes unspeciated)	5 (4.9)	12 (17.1)
Cavitation	26 (25.5)	5 (7.1)
Nodular/interstitial infiltrate	90 (88.2)	40 (57.1)
Bronchiectasis diagnosis by physician or findings on based on CT	43 (42.2)	16 (22.9)
Bronchiectasis findings based on CT only*	36 (35.3)	10 (14.3)
COPD	29 (28.4)	23 (32.9)
Lung cancer	2 (2)	4 (5.7)
Prior tuberculosis	9 (8.8)	3 (4.3)
Prior NTM isolation†	8 (7.8)	1 (1.4)
Cystic fibrosis	2 (2)	1 (1.4)
Other lung disease‡	6 (5.9)	4 (5.7)
Nonsteroid immunosuppressive medication§	10 (9.8)	4 (5.7)
Any steroid use	22 (21.6)	21 (30.0)
Oral prednisone	17 (16.7)	14 (20)
Inhaled corticosteroid with or without LABA	7 (6.9)	9 (12.9)

Definition of abbreviations: COPD = chronic obstructive pulmonary disease; CT = computed tomography; LABA = long-acting β-agonist; NTM = nontuberculous mycobacteria.

Numbers are count (percent) except as noted. Boldface type indicates P < 0.05. Comparison is of patients meeting American Thoracic Society/Infectious Diseases Society of America pulmonary disease case criteria (4) at baseline with those who did not.

^*Ninety cases had CT scan (40% had bronchiectasis); 44 noncases had CT scan (22.7% had bronchiectasis, P = 0.05 for comparison)

^†History of NTM isolation prior to baseline period.

^‡Other lung disease includes interstitial lung disease, sarcoidosis, or allergic bronchopulmonary aspergillosis.

^§Nonsteroid immunosuppressive medications include methotrexate, tacrolimus, cyclosporine, biologics, and azathioprine.